Wedge Capital Management L L P NC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the second quarter, HoldingsChannel reports. The fund bought 380,801 shares of the biotechnology company’s stock, valued at approximately $3,808,000.
Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after purchasing an additional 482,494 shares during the period. RA Capital Management L.P. acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $123,452,000. Deerfield Management Company L.P. grew its position in shares of BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the period. State Street Corp increased its stake in BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after purchasing an additional 1,265,773 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in BioCryst Pharmaceuticals by 20.3% during the 1st quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after buying an additional 1,504,120 shares during the period. 85.88% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on BCRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Needham & Company LLC dropped their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Citizens Jmp boosted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.
BioCryst Pharmaceuticals Stock Performance
NASDAQ BCRX opened at $9.81 on Friday. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.54 and a beta of 0.55. The stock’s 50 day moving average price is $9.47 and its two-hundred day moving average price is $8.82. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.22.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period last year, the business earned $0.15 EPS. The business’s quarterly revenue was up 33.6% on a year-over-year basis. On average, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.44 EPS for the current year.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.
Featured Stories
- Five stocks we like better than BioCryst Pharmaceuticals
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
